{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:01:55Z","timestamp":1762002115230,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ymgmr.2022.100878","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T14:12:06Z","timestamp":1651759926000},"page":"100878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature"],"prefix":"10.1016","volume":"31","author":[{"given":"Vincenza","family":"Gragnaniello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Gueraldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Cazzorla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Massa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Zanconato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto B.","family":"Burlina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ymgmr.2022.100878_bb0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgmr.2022.100878_bb0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jpeds.2019.07.053","article-title":"Population-based newborn screening for mucopolysaccharidosis type ii in Illinois: the first year experience","volume":"214","author":"Burton","year":"2019","journal-title":"J. Pediatr."},{"year":"2022","series-title":"Mucopolysaccharidosis Type II. [Updated 2021 Nov 20]","author":"Hashmi","key":"10.1016\/j.ymgmr.2022.100878_bb0015"},{"issue":"4","key":"10.1016\/j.ymgmr.2022.100878_bb0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ymgme.2012.09.024","article-title":"Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III","volume":"107","author":"de Ruijter","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgmr.2022.100878_bb0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/21678707.2017.1296761","article-title":"Presentation and treatments for mucopolysaccharidosis type II (MPS II; hunter syndrome)","volume":"5","author":"Stapleton","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.ymgmr.2022.100878_bb0030","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13052-018-0552-3","article-title":"Newborn screening in mucopolysaccharidoses","volume":"44","author":"Donati","year":"2018","journal-title":"Ital. J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgmr.2022.100878_bb0035","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1590\/S1415-47572014000300003","article-title":"Guidelines for diagnosis and treatment of hunter syndrome for clinicians in Latin America","volume":"37","author":"Giugliani","year":"2014","journal-title":"Genet. Mol. Biol."},{"issue":"1","key":"10.1016\/j.ymgmr.2022.100878_bb0040","first-page":"251","article-title":"Efficacy of enzyme replacement therapy on the range of motion of the upper and lower extremities in 16 polish patients with mucopolysaccharidosis type II: a long-term follow-up study","volume":"69","author":"Marucha","year":"2022","journal-title":"Acta Biochim. Pol."},{"issue":"1","key":"10.1016\/j.ymgmr.2022.100878_bb0045","first-page":"9","article-title":"Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (hunter syndrome) receiving conventional and novel enzyme replacement therapies: a case report","volume":"62","author":"Tomita","year":"2021","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/j.ymgmr.2022.100878_bb0050","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s13023-021-02052-4","article-title":"Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the hunter outcome survey (HOS)","volume":"16","author":"Muenzer","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgmr.2022.100878_bb0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1254\/fpj.21080","article-title":"Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO\u00ae I.V. Infusion 10\u00a0mg) as the therapeutic for Mucopolysaccharidosis type-II (Hunter syndrome)","volume":"157","author":"Yamamoto","year":"2022","journal-title":"Nihon Yakurigaku Zasshi"},{"issue":"6","key":"10.1016\/j.ymgmr.2022.100878_bb0060","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s10545-018-0221-0","article-title":"The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology","volume":"41","author":"Sohn","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgmr.2022.100878_bb0065","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.ymgmr.2022.100878_bb0070","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.ymgmr.2022.100878_bb0075","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ymgmr.2022.100878_bb0080","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/diagnostics10010046","article-title":"Assessment of activity of daily life in mucopolysaccharidosis type II patients with hematopoietic stem cell transplantation","volume":"10","author":"Suzuki","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"8","key":"10.1016\/j.ymgmr.2022.100878_bb0085","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/ijms21082975","article-title":"Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations","volume":"21","author":"Parini","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.ymgmr.2022.100878_bb0090","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1034\/j.1398-9995.2001.t01-1-00001.x","article-title":"A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force","volume":"56","author":"Johansson","year":"2001","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.ymgmr.2022.100878_bb0095","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2165\/00002018-200124110-00005","article-title":"Preventing and managing drug-induced anaphylaxis","volume":"24","author":"Drain","year":"2001","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.ymgmr.2022.100878_bb0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/WOX.0b013e3181655dde","article-title":"Book review: drug hypersensitivity by W. J. Pichler (Bern)","volume":"1","author":"Ring","year":"2008","journal-title":"World Allerg. Organ J."},{"issue":"12","key":"10.1016\/j.ymgmr.2022.100878_bb0105","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/j.1365-2222.1996.tb00536.x","article-title":"Drug-associated anaphylaxis: 20 years of reporting in the Netherlands (1974-1994) and review of the literature","volume":"26","author":"van der Klauw","year":"1996","journal-title":"Clin. Exp. Allergy"},{"issue":"4","key":"10.1016\/j.ymgmr.2022.100878_bb0110","first-page":"275","article-title":"T-cell reactions to drugs in distinct clinical manifestations of drug allergy","volume":"11","author":"Neukomm","year":"2001","journal-title":"J Investig Allergol Clin Immunol"},{"first-page":"168","year":"2007","series-title":"Drug Hypersensitivity","key":"10.1016\/j.ymgmr.2022.100878_bb0115"},{"issue":"24","key":"10.1016\/j.ymgmr.2022.100878_bb0120","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1001\/jama.1986.03380240052027","article-title":"Drug-induced cutaneous reactions. A report from the Boston collaborative drug surveillance program on 15,438 consecutive inpatients, 1975 to 1982","volume":"256","author":"Bigby","year":"1986","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ymgmr.2022.100878_bb0125","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1542\/peds.2008-0999","article-title":"Multidisciplinary management of hunter syndrome","volume":"124","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.ymgmr.2022.100878_bb0130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/all.12774","article-title":"Drug hypersensitivity in children: report from the pediatric task force of the EAACI drug allergy interest group","volume":"71","author":"Gomes","year":"2016","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.ymgmr.2022.100878_bb0135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ijns5020024","article-title":"Implementation of second-tier tests in newborn screening for lysosomal disorders in north eastern Italy","volume":"5","author":"Burlina","year":"2019","journal-title":"Int. J. Neonatal Screen"},{"issue":"12","key":"10.1016\/j.ymgmr.2022.100878_bb0140","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1515\/cclm-2020-0064","article-title":"The combined use of enzyme activity and metabolite assays as a strategy for newborn screening of mucopolysaccharidosis type I","volume":"58","author":"Polo","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.ymgmr.2022.100878_bb0145","first-page":"71","article-title":"Analysis of long-term observations of the large group of Russian patients with hunter syndrome (mucopolysaccharidosis type II)","volume":"14","author":"Semyachkina","year":"2021","journal-title":"BMC Med. Genet."},{"author":"Elaprase SPC (EMA)","key":"10.1016\/j.ymgmr.2022.100878_bb0150"},{"issue":"2","key":"10.1016\/j.ymgmr.2022.100878_bb0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","article-title":"Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the hunter outcome survey (HOS)","volume":"103","author":"Burton","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgmr.2022.100878_bb0160","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/all.12155","article-title":"IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with hunter syndrome","volume":"68","author":"Kim","year":"2013","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.ymgmr.2022.100878_bb0165","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.clinthera.2015.06.004","article-title":"Enzyme replacement therapies and immunogenicity in lysosomal storage diseases: is there a pattern?","volume":"37","author":"Harmatz","year":"2015","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.ymgmr.2022.100878_bb0170","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","article-title":"The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase","volume":"110","author":"Barbier","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100878_bb0175","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-015-0265-2","article-title":"Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (hunter syndrome)","volume":"10","author":"Pano","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2022.100878_bb0180","first-page":"2","article-title":"Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients","volume":"12","author":"Giugliani","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"11","key":"10.1016\/j.ymgmr.2022.100878_bb0185","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1398-9995.2010.02441.x","article-title":"General considerations on rapid desensitization for drug hypersensitivity - a consensus statement","volume":"65","author":"Cernadas","year":"2010","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.ymgmr.2022.100878_bb0190","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/all.12161","article-title":"Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the drug allergy interest group","volume":"68","author":"Scherer","year":"2013","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.ymgmr.2022.100878_bb0195","first-page":"e41","article-title":"Desensibilizaci\u00f3n con idursulfase en un ni\u00f1o con s\u00edndrome de Hunter (mucopolisacaridosis II) [Idursulfase desensitization in a child with Hunter syndrome (mucopolysaccharidosis II)]","volume":"119","author":"Bustamante","year":"2021","journal-title":"Arch. Argent. Pediatr."},{"issue":"7","key":"10.1016\/j.ymgmr.2022.100878_bb0200","first-page":"571","article-title":"Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (hunter syndrome)","volume":"21","author":"Serrano","year":"2011","journal-title":"J Investig Allergol Clin Immunol"}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922000386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922000386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:52:52Z","timestamp":1762001572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426922000386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":40,"alternative-id":["S2214426922000386"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100878","relation":{},"ISSN":["2214-4269"],"issn-type":[{"type":"print","value":"2214-4269"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100878"}}